Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Share:
Related REGN
Regeneron Is 'One Of The Stronger Growers In Biotech'
Regeneron CEO And CFO Met With Citi: Here Are The Takeaways
Healthcare ratings roundup - new coverage #1 (Seeking Alpha)
Related SNY
The Market In 5 Minutes: It's Brexit Time
Benzinga's M&A Chatter for Wednesday June 22, 2016
Biotech Forum Daily Digest: Tesaro's Huge Week! Brexit Losses Gone, Spotlight On Applied Genetics Technologies (Seeking Alpha)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Related Articles (REGN + SNY)

View Comments and Join the Discussion!